{
  "first_published_at": "2008-03-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084778", 
  "title": "Telbivudine: risk of peripheral neuropathy with pegylated interferon", 
  "tags": "{\"parsed_therapeutic\": [\"gi-hepatology-pancreatic-disorders\", \"infectious-disease\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"GI, hepatology and pancreatic disorders\", \"Infectious disease\"]}", 
  "_document_number": 295, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "gi-hepatology-pancreatic-disorders", 
    "infectious-disease"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Telbivudine: risk of peripheral neuropathy with pegylated interferon</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: March 2008</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Patients who take telbivudine and (pegylated) interferon are at increased risk of peripheral neuropathy. Patients who develop symptoms of peripheral neuropathy should stop taking both medicines<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Telbivudine (Sebivo &#9660;) is a new nucleoside analogue that is indicated for treatment of chronic hepatitis B in adults with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT), and histological evidence of active inflammation or fibrosis (or both).</p><p>The risk of peripheral neuropathy with telbivudine has been under review since the time of licensing.</p><p>Up to the end of January 2008, six cases of peripheral neuropathy have been reported in association with telbivudine monotherapy.</p><p>In an ongoing multicentre trial comparing telbivudine monotherapy with telbivudine and pegylated interferon alfa 2a (Pegasys) combination therapy, eight cases of peripheral neuropathy have been reported in 48 patients. The combination arm of this trial was suspended in January 2008. These cases were serious, occurred in relatively young patients within 3 months of starting treatment, and required treatment discontinuation.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>The combination of telbivudine and interferon cannot be recommended</li>\r\n\t\t\t\t<li>All patients who take telbivudine should be monitored for occurrence of peripheral neuropathy</li>\r\n\t\t\t\t<li>Patients who are taking telbivudine and (pegylated) interferon who develop peripheral neuropathy should stop taking both medicines</li>\r\n\t\t\t\t<li>For patients who are taking telbivudine alone who develop peripheral neuropathy, consideration should be given to stopping this medicine</li>\r\n\t\t\t</ul></div><p><strong>See also:</strong></p><p><a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000713/human_med_001048.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124\" target=\"_blank\">European Public Assessment Report on telbivudine</a></p><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON014108\" target=\"_blank\">Letter on safety information for telbivudine sent to&nbsp;healthcare professionals in February 2008</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Mar 2008; Vol 1, Issue 8: 4</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Telbivudine (Sebivo &#9660;) is a new nucleoside analogue that is indicated for treatment of chronic hepatitis B in adults with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT), and histological evidence of active inflammation or fibrosis (or both).</p><p>The risk of peripheral neuropathy with telbivudine has been under review since the time of licensing.</p><p>Up to the end of January 2008, six cases of peripheral neuropathy have been reported in association with telbivudine monotherapy.</p><p>In an ongoing multicentre trial comparing telbivudine monotherapy with telbivudine and pegylated interferon alfa 2a (Pegasys) combination therapy, eight cases of peripheral neuropathy have been reported in 48 patients. The combination arm of this trial was suspended in January 2008. These cases were serious, occurred in relatively young patients within 3 months of starting treatment, and required treatment discontinuation.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>The combination of telbivudine and interferon cannot be recommended</li>\r\n\t\t\t\t<li>All patients who take telbivudine should be monitored for occurrence of peripheral neuropathy</li>\r\n\t\t\t\t<li>Patients who are taking telbivudine and (pegylated) interferon who develop peripheral neuropathy should stop taking both medicines</li>\r\n\t\t\t\t<li>For patients who are taking telbivudine alone who develop peripheral neuropathy, consideration should be given to stopping this medicine</li>\r\n\t\t\t</ul></div><p><strong>See also:</strong></p><p><a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000713/human_med_001048.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d124\" target=\"_blank\">European Public Assessment Report on telbivudine</a></p><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON014108\" target=\"_blank\">Letter on safety information for telbivudine sent to&#160;healthcare professionals in February 2008</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Mar 2008; Vol 1, Issue 8: 4</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2008-03-01", 
  "date_last_modified": "2010-09-14", 
  "_assets": [], 
  "_item_id": 295, 
  "summary": "Patients who take telbivudine and (pegylated) interferon are at increased risk of peripheral neuropathy. Patients who develop symptoms of peripheral neuropathy should stop taking both medicines", 
  "body": "Article date: March 2008\n\nTelbivudine (Sebivo ▼) is a new nucleoside analogue that is indicated for treatment of chronic hepatitis B in adults with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT), and histological evidence of active inflammation or fibrosis (or both).\n\nThe risk of peripheral neuropathy with telbivudine has been under review since the time of licensing.\n\nUp to the end of January 2008, six cases of peripheral neuropathy have been reported in association with telbivudine monotherapy.\n\nIn an ongoing multicentre trial comparing telbivudine monotherapy with telbivudine and pegylated interferon alfa 2a (Pegasys) combination therapy, eight cases of peripheral neuropathy have been reported in 48 patients. The combination arm of this trial was suspended in January 2008. These cases were serious, occurred in relatively young patients within 3 months of starting treatment, and required treatment discontinuation.\n\nAdvice for healthcare professionals:  \n  \n  * The combination of telbivudine and interferon cannot be recommended  \n  * All patients who take telbivudine should be monitored for occurrence of peripheral neuropathy  \n  * Patients who are taking telbivudine and (pegylated) interferon who develop peripheral neuropathy should stop taking both medicines  \n  * For patients who are taking telbivudine alone who develop peripheral neuropathy, consideration should be given to stopping this medicine  \n  \nSee also:\n\n[European Public Assessment Report on telbivudine](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000713/human_med_001048.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124)\n\n[Letter on safety information for telbivudine sent to healthcare professionals in February 2008](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON014108)\n\n \n\nArticle citation: Drug Safety Update Mar 2008; Vol 1, Issue 8: 4\n"
}